Delcath Systems announces first commercial use of HEPZATO KIT for mUM

Delcath Systems announced the first commercial use of HEPZATO KIT for the treatment of metastatic uveal melanoma, or mUM. The procedure took place at Moffitt Cancer Center in Tampa, Florida by Dr. Jonathan S. Zager, Chief Academic Officer; Senior Member, Department of Cutaneous, Oncology; Director of Regional Therapies, Moffitt Cancer Center. Dr. Zager was the global Lead Investigator for the FOCUS Phase 3 trial. The company is working with numerous other leading cancer centers across the U.S. which have indicated interest in HEPZATO KIT to ensure patients nationwide have access to this important treatment. In conjunction with the first commercial treatment, Delcath also launched websites relating to the HEPZATO KIT, including HEPZATO KIT, HEPZATO KIT REMS, and HEPZATO KIT Access, to support the commercial launch.